Key Takeaways
- Clinical Bottom Line
- Navigating Gallbladder Polyps in 2026
- Differentiating Polyp Types
- Evidence-Based Management and Surveillance
Clinical Bottom Line
| Polyp Size | Recommended Clinical Action (2025/2026 Guidelines) |
|---|---|
| Under 5 mm | No follow-up required in asymptomatic patients without risk factors for malignancy. |
| 6 to 9 mm | Follow-up ultrasound at 1 year. If stable, discontinue surveillance. If growing, consider cholecystectomy. |
| 10 mm or larger | Laparoscopic cholecystectomy is recommended due to a significantly increased risk of malignant transformation. |
| High-Risk Features | Consider cholecystectomy for polyps of any size if associated with Primary Sclerosing Cholangitis (PSC) or growing rapidly. |
Navigating Gallbladder Polyps in 2026
Gallbladder polyps are outgrowths of the mucosal wall of the gallbladder. Driven by the widespread use of high-resolution abdominal ultrasonography for non-specific abdominal pain, they are now identified in up to 5% of healthy adults. The vast majority of these lesions are entirely benign; the clinical challenge lies in identifying the rare adenomatous polyps that act as precursors to gallbladder carcinoma.
Differentiating Polyp Types
Not all polyps carry neoplastic potential. They are broadly categorized into pseudo-polyps and true polyps.
Pseudo-polyps (Benign)
Accounting for nearly 70% of all gallbladder polyps, these lesions have zero potential for malignant transformation.
- Cholesterol Polyps: The most common subtype. They are caused by the abnormal focal accumulation of cholesterol-laden macrophages within the lamina propria. They are often multiple, small (usually <5 mm), and attached via a fragile stalk.
- Inflammatory Polyps: Composed of granulation tissue and chronic inflammatory cells, often associated with chronic cholecystitis.
- Adenomyomatosis: Hyperplasia of the muscularis resulting in invaginations (Rokitansky-Aschoff sinuses) that can mimic polypoid growth.
True Polyps (Neoplastic Potential)
True adenomas are rare but follow a distinct adenoma-carcinoma sequence similar to colorectal cancer.
- Adenomatous Polyps: True neoplastic outgrowths. They are typically solitary, larger, and have a broader base (sessile) than cholesterol polyps. As they increase in size, the risk of harboring dysplasia or invasive carcinoma rises exponentially.
Evidence-Based Management and Surveillance
Because ultrasound cannot reliably differentiate between a benign cholesterol polyp and a pre-malignant adenoma based solely on morphology, clinical guidelines (such as those jointly published by European societies ESGAR, EAES, EFISDS, and ESGE) rely heavily on polyp size as the primary predictor of malignancy.
Polyps > 10 mm
A polyp measuring 10 mm (1 cm) or larger indicates a substantial risk of malignancy (up to 25%). Laparoscopic cholecystectomy is definitively recommended for patients fit for surgery, regardless of symptoms.
Polyps 6 to 9 mm
Management depends on the presence of patient-level risk factors (e.g., age >50, concurrent primary sclerosing cholangitis (PSC), sessile morphology, or Indian ethnicity).
- With Risk Factors: Cholecystectomy should be strongly considered and discussed with the patient.
- Without Risk Factors: Surveillance ultrasound is recommended at 1 year, 2 years, and 5 years. If the polyp grows by 2 mm or more during follow-up, it is an indication for surgery. If it remains stable after 5 years, surveillance can cease.
Polyps < 5 mm
Recent updates have significantly de-escalated surveillance for diminutive polyps.
- Without Risk Factors: No regular follow-up is necessary. The risk of malignancy is virtually negligible, and they are overwhelmingly cholesterol pseudo-polyps.
- With Risk Factors: Follow-up ultrasound at 1, 3, and 5 years is advised.
The Primary Sclerosing Cholangitis (PSC) Exception
Patients with PSC represent a uniquely high-risk cohort. Due to the high rate of rapid malignant transformation and underlying biliary pathology, current guidelines recommend considering a cholecystectomy for a gallbladder polyp of any size in a patient with documented PSC.
Clinical guidelines summarized by the Gastroscholar Research Team. Last updated: April 16, 2026. This article is intended for physicians and surgical trainees.
